Cleerly ISCHEMIA vs ZEUS System (Zio Watch)
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you need a non-invasive, detailed assessment of coronary artery disease, particularly for evaluating the likelihood of ischemia and characterizing coronary plaque. This tool is ideal for patients undergoing CCTA scans where physicians require AI-powered analysis to understand vessel-level blood flow and inform personalized treatment strategies.
View Cleerly ISCHEMIA →Choose ZEUS System (Zio Watch) if…
Choose the ZEUS System (Zio Watch) if you require long-term continuous cardiac monitoring to detect and characterize intermittent or paroxysmal arrhythmias, such as Atrial Fibrillation. This wearable solution is best suited for patients experiencing symptoms suggestive of arrhythmias or those needing extended monitoring beyond a typical in-office ECG to capture elusive cardiac events.
View ZEUS System (Zio Watch) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | ZEUS System (Zio Watch) |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Web-based solution | Cloud-based system with a wearable device |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS System (Zio Watch)Tool B offers a more comprehensive user experience by integrating a wearable device for patients, a dedicated patient app for symptom logging and education, and a provider portal/mobile app. While Tool A provides interactive web-based reports and integration with PowerScribe for clinicians, Tool B's holistic approach involving both patient and provider tools gives it an edge in overall usability across the care continuum.
Clinical Value
ZEUS System (Zio Watch)Both tools are FDA-cleared and offer significant clinical value in cardiology. However, Tool B explicitly highlights 'clinically actionable reports with high physician agreement (99%)' for its arrhythmia detection, providing a strong, quantifiable metric of its reliability and utility in practice. While Tool A's non-invasive FFR estimation and plaque characterization are highly valuable, the stated physician agreement for Tool B offers a clearer indication of its immediate clinical impact and acceptance.
Pricing & Value
TieBoth Tool A and Tool B require direct contact for pricing details, making it impossible to assess their relative pricing transparency or value proposition from the provided information. Neither tool offers publicly available pricing structures or detailed cost-benefit analyses.
Enterprise Readiness
Cleerly ISCHEMIABoth tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and Business Associate Agreements (BAAs). However, Tool A explicitly mentions 'Integration with PowerScribe via API,' which is a critical feature for seamless integration into existing radiology department workflows and enterprise imaging systems, giving it a slight advantage in practical enterprise deployment.
Innovation
ZEUS System (Zio Watch)Both tools leverage AI in innovative ways for cardiac diagnostics. Tool B's combination of an AI-powered wearable biosensor for long-term continuous ECG and PPG data collection, advanced arrhythmia detection, and a comprehensive patient/provider app ecosystem represents a significant innovation in remote patient monitoring and early detection. While Tool A's non-invasive FFR estimation from CCTA is also highly innovative, Tool B's approach with a continuous wearable for extended monitoring offers a more transformative shift in how cardiac arrhythmias are diagnosed and managed.
Support & Docs
TieNeither the provided structured facts nor general web search results offer specific details regarding the level of customer support, available documentation, training programs, or service level agreements for either Tool A or Tool B. Without this information, it is not possible to distinguish between them on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | ZEUS System (Zio Watch) |
|---|---|---|
| Name | Cleerly ISCHEMIA | ZEUS System (Zio Watch) |
| Company | Cleerly | iRhythm Technologies |
| Primary Use Case | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Long-term continuous cardiac monitoring to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians. |
| Data Input Method | CCTA scans | Wearable biosensor (Zio Watch) for continuous ECG and PPG data collection |
| Key Output | AI-enabled CCTA analysis, non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), stenosis severity assessment, 3D digital models of coronary arteries, comprehensive interactive web-based reports. | AI-powered algorithm (ZEUS System) for advanced arrhythmia detection and analysis, long-term continuous monitoring for up to 14 days, detects and characterizes Atrial Fibrillation (AFib) burden, cloud-based data analytics and processing, clinically actionable reports with high physician agreement (99%). |
| Specialties | Cardiology, Radiology | Cardiology, Family Medicine, Internal Medicine |
| Monitoring Duration | Not specified | Up to 14 days (long-term continuous monitoring) |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and ZEUS System (Zio Watch).
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or ZEUS System (Zio Watch)
Backers
Who funded each tool's parent company.